Scynexis said on Monday it would voluntarily recall its antifungal pill, which it has licensed to GSK, due to risk of cross-contamination with a potential allergy-inducing compound, sending the drugmaker's shares tumbling 32% premarket.
https://finance.yahoo.com/news/1-scynexis-recall-gsk-partnered-125556041.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.